S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Forecast, Price & News

$58.47
+1.86 (+3.29%)
(As of 06/9/2023 ET)
Compare
Today's Range
$56.57
$59.15
50-Day Range
$42.20
$60.03
52-Week Range
$37.82
$79.40
Volume
411,762 shs
Average Volume
660,872 shs
Market Capitalization
$3.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.11

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
28.1% Upside
$74.89 Price Target
Short Interest
Healthy
5.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.11mentions of Blueprint Medicines in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$120,102 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.55) to ($7.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

347th out of 988 stocks

Pharmaceutical Preparations Industry

157th out of 482 stocks


BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Blueprint Medicines (NASDAQ:BPMC) Shares Gap Down to $58.22
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Update
Analyst Expectations for Blueprint Medicines's Future
See More Headlines

BPMC Price History

BPMC Company Calendar

Last Earnings
5/04/2023
Today
6/10/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
495
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$74.89
High Stock Price Forecast
$114.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+25.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
15 Analysts

Profitability

Net Income
$-557,520,000.00
Net Margins
-284.02%
Pretax Margin
-281.29%

Debt

Sales & Book Value

Annual Sales
$204.04 million
Book Value
$8.60 per share

Miscellaneous

Free Float
58,121,000
Market Cap
$3.54 billion
Optionable
Optionable
Beta
0.71

Social Links


Key Executives

  • Kathryn HavilandKathryn Haviland
    President, Chief Executive Officer & Director
  • Christina RossiChristina Rossi
    Chief Operating Officer
  • Michael Landsittel
    Chief Financial Officer
  • Christopher K. Murray
    Senior Vice President-Technical Operations
  • Janet Loesberg
    Senior Vice President-Global Medical Affairs













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2023?

15 equities research analysts have issued 12-month price targets for Blueprint Medicines' shares. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they anticipate the company's share price to reach $74.89 in the next twelve months. This suggests a possible upside of 28.1% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2023?

Blueprint Medicines' stock was trading at $43.81 at the beginning of 2023. Since then, BPMC shares have increased by 33.5% and is now trading at $58.47.
View the best growth stocks for 2023 here
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) posted its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($2.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.66) by $0.51. The biotechnology company earned $63.29 million during the quarter, compared to analysts' expectations of $41.85 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 100.31% and a negative net margin of 284.02%. The firm's revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.79) earnings per share.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.59%), BlackRock Inc. (10.95%), Wellington Management Group LLP (8.50%), Price T Rowe Associates Inc. MD (8.18%), State Street Corp (4.56%) and JPMorgan Chase & Co. (2.57%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $58.47.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.54 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 495 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -